PSDV has been the subject of a number of other research reports. Ladenburg Thalmann Financial Services set a $13.00 price objective on pSivida Corp. and gave the company a buy rating in a research report on Wednesday, June 14th. Rodman & Renshaw initiated coverage on pSivida Corp. in a research report on Tuesday, May 30th. They set a buy rating and a $8.00 price objective for the company. FBR & Co restated a buy rating on shares of pSivida Corp. in a research report on Wednesday, June 14th. Finally, Northland Securities set a $10.00 price objective on pSivida Corp. and gave the company a buy rating in a research report on Wednesday, June 14th. Five research analysts have rated the stock with a buy rating, pSivida Corp. has a consensus rating of Buy and an average price target of $8.60.
Shares of pSivida Corp. (NASDAQ PSDV) opened at 1.21 on Tuesday. pSivida Corp. has a 1-year low of $1.03 and a 1-year high of $3.52. The stock has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.64. The company’s market cap is $46.79 million.
pSivida Corp. (NASDAQ:PSDV) last issued its quarterly earnings data on Monday, September 11th. The company reported ($0.16) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.16). The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.48 million. pSivida Corp. had a negative return on equity of 132.95% and a negative net margin of 245.19%. Equities research analysts forecast that pSivida Corp. will post ($0.59) earnings per share for the current year.
A hedge fund recently raised its stake in pSivida Corp. stock. Renaissance Technologies LLC increased its stake in pSivida Corp. (NASDAQ:PSDV) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 963,043 shares of the company’s stock after acquiring an additional 56,043 shares during the period. Renaissance Technologies LLC owned approximately 2.82% of pSivida Corp. worth $1,656,000 as of its most recent SEC filing. 14.95% of the stock is owned by hedge funds and other institutional investors.
About pSivida Corp.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with our FREE daily email newsletter.